Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 16 | 2023 | 135 | 3.930 |
Why?
|
| Immunotherapy, Adoptive | 13 | 2023 | 155 | 2.660 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 11 | 2023 | 865 | 2.350 |
Why?
|
| Lymphoma, Mantle-Cell | 3 | 2023 | 33 | 1.910 |
Why?
|
| Lymphoma, Non-Hodgkin | 5 | 2023 | 259 | 1.450 |
Why?
|
| Antigens, CD19 | 10 | 2023 | 39 | 1.430 |
Why?
|
| Lymphoma, B-Cell | 5 | 2022 | 102 | 1.350 |
Why?
|
| Transplantation, Autologous | 6 | 2021 | 324 | 1.120 |
Why?
|
| Jehovah's Witnesses | 1 | 2021 | 18 | 0.810 |
Why?
|
| Blood Component Removal | 1 | 2020 | 24 | 0.810 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2018 | 115 | 0.810 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 187 | 0.780 |
Why?
|
| Biological Products | 4 | 2023 | 136 | 0.770 |
Why?
|
| Transplantation Conditioning | 3 | 2021 | 372 | 0.760 |
Why?
|
| Lymphoma | 2 | 2018 | 259 | 0.720 |
Why?
|
| Receptors, Antigen, T-Cell | 5 | 2023 | 363 | 0.620 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 2390 | 0.580 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2016 | 78 | 0.570 |
Why?
|
| Lymphoma, Follicular | 3 | 2022 | 69 | 0.560 |
Why?
|
| Graft vs Host Disease | 3 | 2023 | 359 | 0.520 |
Why?
|
| Hepatitis B virus | 1 | 2014 | 38 | 0.510 |
Why?
|
| Hepatitis B | 1 | 2014 | 69 | 0.490 |
Why?
|
| Humans | 42 | 2023 | 83873 | 0.470 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 712 | 0.460 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1355 | 0.430 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2023 | 135 | 0.420 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2023 | 1257 | 0.420 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2023 | 185 | 0.380 |
Why?
|
| Cell- and Tissue-Based Therapy | 4 | 2023 | 49 | 0.370 |
Why?
|
| Retrospective Studies | 8 | 2023 | 8061 | 0.350 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 2324 | 0.350 |
Why?
|
| T-Lymphocytes | 4 | 2021 | 1176 | 0.300 |
Why?
|
| Sarcopenia | 2 | 2016 | 13 | 0.300 |
Why?
|
| Aged | 13 | 2023 | 18098 | 0.280 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2023 | 9 | 0.240 |
Why?
|
| Adult | 11 | 2023 | 25203 | 0.240 |
Why?
|
| Survival Analysis | 3 | 2023 | 1531 | 0.230 |
Why?
|
| Veterans | 4 | 2016 | 64 | 0.230 |
Why?
|
| Rituximab | 4 | 2016 | 113 | 0.220 |
Why?
|
| Middle Aged | 11 | 2022 | 24691 | 0.220 |
Why?
|
| Hodgkin Disease | 1 | 2023 | 173 | 0.210 |
Why?
|
| Geriatric Assessment | 2 | 2020 | 161 | 0.210 |
Why?
|
| 5-Methylcytosine | 1 | 2022 | 106 | 0.210 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 177 | 0.210 |
Why?
|
| United States | 7 | 2023 | 6425 | 0.200 |
Why?
|
| Prognosis | 2 | 2018 | 3618 | 0.190 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 918 | 0.190 |
Why?
|
| Cladribine | 1 | 2019 | 35 | 0.190 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 41 | 0.190 |
Why?
|
| Carcinoma | 1 | 2023 | 427 | 0.180 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 321 | 0.180 |
Why?
|
| Male | 13 | 2023 | 40239 | 0.180 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 127 | 0.170 |
Why?
|
| Patient Selection | 2 | 2019 | 680 | 0.170 |
Why?
|
| Female | 12 | 2023 | 43741 | 0.160 |
Why?
|
| Disease Management | 1 | 2019 | 323 | 0.160 |
Why?
|
| Patient Care Team | 1 | 2019 | 274 | 0.160 |
Why?
|
| Preoperative Care | 1 | 2019 | 393 | 0.160 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 80 | 0.160 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 299 | 0.150 |
Why?
|
| Translocation, Genetic | 1 | 2017 | 265 | 0.150 |
Why?
|
| Obesity, Abdominal | 1 | 2016 | 7 | 0.150 |
Why?
|
| Cyclophosphamide | 4 | 2021 | 296 | 0.150 |
Why?
|
| Remission Induction | 3 | 2023 | 709 | 0.150 |
Why?
|
| Body Composition | 1 | 2016 | 64 | 0.140 |
Why?
|
| Up-Regulation | 1 | 2018 | 698 | 0.140 |
Why?
|
| Recurrence | 3 | 2023 | 1136 | 0.140 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 270 | 0.140 |
Why?
|
| Stem Cell Transplantation | 3 | 2021 | 181 | 0.140 |
Why?
|
| Anthracyclines | 1 | 2015 | 35 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 310 | 0.130 |
Why?
|
| Doxorubicin | 4 | 2016 | 284 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 295 | 0.130 |
Why?
|
| Survivors | 1 | 2016 | 217 | 0.130 |
Why?
|
| Febrile Neutropenia | 1 | 2014 | 14 | 0.130 |
Why?
|
| Pandemics | 1 | 2020 | 693 | 0.120 |
Why?
|
| Heart Failure | 1 | 2023 | 1153 | 0.120 |
Why?
|
| Venous Thromboembolism | 1 | 2016 | 143 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 737 | 0.120 |
Why?
|
| Transplantation, Homologous | 3 | 2020 | 985 | 0.120 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2023 | 73 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1181 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1155 | 0.120 |
Why?
|
| Time Factors | 1 | 2021 | 5176 | 0.110 |
Why?
|
| Adolescent | 2 | 2023 | 8806 | 0.110 |
Why?
|
| Vincristine | 3 | 2016 | 109 | 0.110 |
Why?
|
| Prednisone | 3 | 2016 | 254 | 0.100 |
Why?
|
| Body Mass Index | 1 | 2014 | 764 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2014 | 494 | 0.100 |
Why?
|
| Neoplasms | 1 | 2023 | 2794 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2021 | 816 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1357 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2023 | 4090 | 0.080 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6453 | 0.060 |
Why?
|
| Troponin | 1 | 2023 | 18 | 0.060 |
Why?
|
| Melphalan | 1 | 2023 | 96 | 0.060 |
Why?
|
| Outpatients | 1 | 2023 | 87 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 189 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2023 | 240 | 0.050 |
Why?
|
| Thiotepa | 1 | 2021 | 32 | 0.050 |
Why?
|
| Histiocytes | 1 | 2021 | 22 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 242 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2023 | 297 | 0.050 |
Why?
|
| Incidence | 2 | 2016 | 1565 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2021 | 148 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2019 | 7776 | 0.050 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 24 | 0.050 |
Why?
|
| Chimerism | 1 | 2020 | 37 | 0.050 |
Why?
|
| Filgrastim | 1 | 2019 | 56 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 50 | 0.050 |
Why?
|
| Hydrazines | 1 | 2019 | 29 | 0.050 |
Why?
|
| Health Care Rationing | 1 | 2020 | 79 | 0.050 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 56 | 0.050 |
Why?
|
| Standard of Care | 1 | 2019 | 78 | 0.050 |
Why?
|
| Triazoles | 1 | 2019 | 96 | 0.040 |
Why?
|
| Cytarabine | 1 | 2019 | 216 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 580 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 447 | 0.040 |
Why?
|
| Palliative Care | 1 | 2019 | 241 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 252 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2020 | 442 | 0.040 |
Why?
|
| Steroids | 1 | 2018 | 170 | 0.040 |
Why?
|
| Biomarkers | 1 | 2023 | 1654 | 0.040 |
Why?
|
| Abdominal Fat | 1 | 2016 | 13 | 0.040 |
Why?
|
| Subcutaneous Fat | 1 | 2016 | 16 | 0.040 |
Why?
|
| Neutropenia | 1 | 2016 | 213 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2021 | 2703 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2015 | 109 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 852 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 438 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 3025 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 980 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1033 | 0.030 |
Why?
|
| Animals | 2 | 2023 | 26005 | 0.030 |
Why?
|
| Mutation | 1 | 2022 | 3889 | 0.020 |
Why?
|
| Hospitalization | 1 | 2016 | 809 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 10930 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 5843 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2497 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3253 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 5301 | 0.020 |
Why?
|